Why do Wegovy users face sudden sight loss?

New study links semaglutide to optic‑nerve blood‑flow events

Researchers report a striking safety signal: people taking the higher‑dose semaglutide formulation used for weight loss have a much higher rate of abrupt vision loss caused by reduced blood flow to the optic nerve. The analysis compared patients on the brand prescribed for obesity with those taking semaglutide for diabetes at lower doses and found nearly a fivefold increase in cases of so‑called "eye strokes" among the weight‑loss group.

An "eye stroke" is not the same as a brain stroke but describes a sudden interruption of blood supply to the optic nerve, which can cause rapid and often permanent vision loss. Investigators say the pattern is biologically plausible because semaglutide affects vascular and metabolic pathways that could, in susceptible people, impair microvascular blood flow.

Why this matters now

• Use of semaglutide for weight loss has expanded rapidly, meaning even rare adverse events can affect many people.
• Sudden vision loss is a devastating outcome with long‑term disability implications.

What clinicians and patients should watch for

• New, sudden dimming, blurring, or loss of part of the visual field.
• Pain is not always present with these events.

If these symptoms occur, urgent ophthalmic evaluation is warranted. Clinicians should ask patients starting or on higher‑dose semaglutide about preexisting vascular risk factors (for example, diabetes, high blood pressure, or clotting disorders) and consider closer monitoring for visual complaints. Regulators and drug makers will need to examine whether this signal reflects a true causal risk, whether it is dose‑related, and what risk‑mitigation steps are needed. For patients, the key takeaway is to report any sudden changes in vision immediately and not to dismiss them as routine side effects.